English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Serum levels of alpha-lactalbumin were assayed using a monoclonal antibody specific for this breast specific molecule. Elevated levels were found in 87% (48/55) of sera from women in the third trimester of pregnancy (29.1 +/- 7.4 ng ml-1), from 64% (62/97) of patients with breast cancer (23.4 +/- 5.6 ng ml-1), and from 70% (56/80) of patients with gynaecological cancers (19.4 +/- 6.7 ng ml-1). These alpha-lactalbumin levels were significantly higher (P less than 0.001) than those for men and non-pregnant women (11.0 +/- 2.3 ng ml-1) and for patients with other, non-gynaecological cancers (13.4 +/- 3.6 ng ml-1). The alpha-lactalbumin levels were higher in patients with stage IV breast cancer than those with stage I-III breast cancer. The overall sensitivity and specificity of the radioimmunoassay were 72% and 75% respectively. These findings suggest that the assessment of serum levels of alpha-lactalbumin may be useful as a marker for monitoring breast cancer.

Serum human α-lactalbumin as a marker for breast cancer